


Amrinone

| | | | |
|---------------------------|---|-------|----------|
| Cat. No.: | HY-B1294 | | |
| CAS No.: | 60719-84-8 | | |
| Molecular Formula: | C ₁₀ H ₉ N ₃ O | | |
| Molecular Weight: | 187.2 | | |
| Target: | Phosphodiesterase (PDE) | | |
| Pathway: | Metabolic Enzyme/Protease | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



BIOLOGICAL ACTIVITY

| | |
|--------------------|---|
| Description | Amrinone (Inamrinone) is a positive inotropic-vasodilator agent. Amrinone is a selective phosphodiesterase III inhibitor that increases cyclic adenosine monophosphate by preventing its breakdown. Amrinone is also an orally active, non-glycosidic and non-catecholamine cardiostimulant agent ^{[1][2][3]} . |
| In Vitro | Amrinone (Inamrinone) produced a dose-dependent inhibition of ADP-induced rat platelet aggregation in vitro as well as ex vivo in rats. The proliferation of human aortic smooth muscle cells in culture stimulated with FBS or PDGF was also inhibited by amrinone ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| In Vivo | Amrinone (Inamrinone) is administered subcutaneously to rats at a dose of 10 mg/kg/day for 14 days, significant reduction of neointimal thickness was noted ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

- [1]. M Hachisu, et al. [Effects of Amrinone, an Inhibitor of c-AMP-specific Phosphodiesterases, on Neointimal Hyperplasia After Balloon Injury in Rats]. *Nihon Yakurigaku Zasshi*. 1998 Oct;112(4):267-74.
- [2]. A A Alousi, et al. The Beneficial Effect of Amrinone on Acute Drug-Induced Heart Failure in the Anaesthetised Dog. *Cardiovasc Res*. 1985 Aug;19(8):483-94.
- [3]. S Ichioka, et al. Clinical Use of Amrinone (A Selective Phosphodiesterase III Inhibitor) in Reconstructive Surgery. *Plast Reconstr Surg*. 2001 Dec;108(7):1931-7.
- [4]. T H LeJemtel, et al. Amrinone: A New Non-Glycosidic, Non-Adrenergic Cardiostimulant Effective in the Treatment of Intractable Myocardial Failure in Man. *Circulation*. 1979 Jun;59(6):1098-104.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA